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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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HDSA’s renewed commitment to critical research

After a budgetary crisis that practically eliminated support to HD
scientists in recent years, the Huntington’s Disease Society of
America (HDSA) has committed itself to reestablishing a program
of research projects critical for developing effective treatments.
In a September 28 e-mail message to “HDSA friends,” HDSA
CEO Louise Vetter announced the hiring of George Yohrling,
Ph.D., to fill the new position of Director of Medical & Scientific
Affairs.
“In the past we have relied upon the volunteer support and
consultation of physicians and scientists,” Vetter explained in an
interview in San Diego on November 16. “We will continue to do
so. But based on what the pace of HD research is right now and
our vision to have a new research program, we felt it was the right
time to bring that expertise in-house.”
Dr. Yohrling, a molecular neuroscientist, has worked in the HD
field since 2000.
“His first job was with an HDSA Coalition for the Cure lab,”
Vetter said. “He was funded with an HDSA grant, and he has
continued to stay in the field.... He has real expertise in HD, which
is incredibly important. His primary task is to launch a new
research program for the organization.”
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The hire marks the first step in fulfilling a series of goals outlined
in HDSA’s first-ever strategic plan, formulated after broad
consultation with the HD community in 2011 and 2012, and
launched by Vetter at the annual HDSA convention last June (click
here to read a report on the drafting of the plan).
In response to recent criticisms of HDSA because of the drastic
decline in research support (click here to read more), Vetter stated
that HDSA is working “to have the most impact for the most
people and help set the course for the best care and the best
treatments as soon as possible.”
(Watch the entirety of my interview with Vetter in the video
below.)
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CEO Louise Vetter on HDSA's new directions
from Gene Veritas

12:24

Avoiding repetition
In crafting the new research program, HDSA planners took into
account the organization’s limited budget (about $8.5 million
annually) and strived to avoid duplicating efforts by other HD
initiatives focused strictly on research, Vetter added.
Those initiatives include the CHDI Foundation, Inc., which spends
tens of millions of dollars annually, and the Hereditary Disease
Foundation (HDF). Unlike HDSA, they do not offer support
groups, care centers, or other forms of patient outreach.
Both Vetter and Dr. Yohrling emphasized that the new research
program will focus on HD research in humans and human cells.
This contrasts sharply with – but also necessarily complements –
the research conducted on animals.
Focusing on humans
“We’re calling it ‘Human HD Biology Project,’” Dr. Yohrling said
in a November 26 interview. “All of the observations will be from
human HD patients, and not from a worm or mouse or fly. There’ll
be no arguing about the physiological relevance of the data we will
acquire.”
Dr. Yorhling explained that the project will function like a postdoctoral or clinical fellowship program. Young scientists will
partner with the directors of HDSA’s 21 Centers of Excellence for
Family Services and Research, which see patients and other HD
family members on a regular basis. It replaces the Coalition for the
Cure grant program, which ceased to exist with the onset of the
budget crisis.
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Dr. George Yohrling (CHDI photo)

The new researchers will focus on tasks such as the search for
human biomarkers – specific signs of the disease within bodily
fluids or tissues or the brain, for example – that will become
crucial for measuring the effects of potential remedies.
“These are studies, not clinical trials, but their outcome could and
should help support, drive, and steer clinical trials,” Dr. Yohrling
explained, adding that he is currently recruiting HD specialists to
serve on the program’s advisory committee, which will review the
applications from researchers.
Grants will be relatively modest, Dr. Yorhling indicated. “These
won’t be $250,000 jobs,” he said. However, because of the clear
emphasis on non-redundancy, “hopefully we’ll get a big bang for
our buck,” he added.
HDSA has already raised funds to kick off the project, Dr.
Yorhling said, although both he and CEO Vetter recognized the
need to increase fundraising to expand support for research.
HDSA hopes to issue its first call for proposals in early 2013, Dr.
Yohrling said.
HDSA also will continue to support an important consortium of
HD stem cell researchers, he noted.
A pivotal player
Dr. Yohrling’s diverse experience in HD research makes him a
pivotal player in the search for treatments.
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After receiving his Ph.D. in pharmacology from Wake Forest
University in 2000, he became the very first post-doctoral
researcher in the lab of Jang-Ho Cha, M.D., Ph.D., at Harvard
Medical School/Massachusetts General Hospital. (Dr. Cha is a
member of the HDSA Board of Trustees and will chair the HD
Human Biology Project Advisory committee.) During his two
years under Dr. Cha, he “got to see and interact with HD
firsthand.”
“Any human being with a soul in their body” would be motivated
to help, Dr. Yohrling recalls of his initial, serendipitous contact
with Dr. Cha and the HD team while in Boston searching for a
post-doctoral position. “I was hooked. I felt it was my calling.”
Under Dr. Cha, Dr. Yohrling also received an HDF grant.
Dr. Yorhling spent the next five years conducting Alzeimer’s
disease research at the pharmaceutical giant Johnson & Johnson,
followed by two years at Galleon Pharmaceuticals, Inc.,
researching respiratory conditions.
In 2009 Dr. Yohrling joined CHDI, which he described as a
“dream” of an opportunity to focus fully on HD research in a
large, resource-rich organization. There he served as director of
target assessment and then director of systems biology-pathway
assessment. Working with firms and leading HD scientists, he
managed millions of dollars in research contracts. He also led the
development of HD Research Crossroads, an online repository of
HD-relevant drug target validation data.
Impacting patients with ‘all hands on deck’
CHDI was “more a behind-the-scenes operation,” Dr. Yohrling
observed. “HDSA is more of a grassroots, family-oriented
foundation. The opportunity to get back to that, while also getting
involved in human biology research, was an opportunity too good
to ignore.”
Responding to the argument that HDSA should let others
concentrate on research while putting funds strictly into social
services, Dr. Yohrling observed that the HDSA board and HD
families want the organization “back involved in research and not
to leave it up to the other entities like CHDI, HDF, and the
government,” although his key responsibilities will include
maintaining “an open line of communications” with those and
other HD research organizations.
“We’re really glad to have someone like George working at
HDSA,” said Robi Blumenstein, the president of CHDI
Management, Inc., which carries out the day-to-day tasks of
CHDI’s mission. “It just furthers our ability to collaborate.”
“I think that HDSA is well-positioned with their centers of
excellence around the country,” Dr. Yohrling continued. “This is
curehd.blogspot.com/2012/11/hdsas-renewed-commitment-to-critical.html
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an incredible resource. It’s a huge benefit that HDSA has over
other foundations or organizations, this access and close
connection to the patients. A research program, although it might
be limited initially, if the money is use properly and thoughtfully,
can have a huge impact on the lives of patients.”
“We need all hands on deck,” said Vetter, adding that everybody in
the HD community can take small but important steps to help the
cause by keeping in touch with attending physicians, learning
about HD research, and participating in clinical trials and research
studies. “As we look at the dawn of a new time of HD therapeutic
development, the only way those drugs are going to come to
market is if people get involved. Getting involved is the most
important thing that the HD community can do right now.”
Posted by Gene Veritas at 12:54 PM
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